[1]
|
王劲松, 魏家燕, 彭敏. 2023年美国癌症统计报告和全球最新癌症统计数据解读及启示[J]. 实用肿瘤杂志, 2023, 38(6): 523-527. https://doi.org/10.13267/j.cnki.syzlzz.2023.083
|
[2]
|
Ventriglia, J., Paciolla, I., Pisano, C., Cecere, S.C., Di Napoli, M., Tambaro, R., et al. (2017) Immunotherapy in Ovarian, Endometrial and Cervical Cancer: State of the Art and Future Perspectives. Cancer Treatment Reviews, 59, 109-116.
https://doi.org/10.1016/j.ctrv.2017.07.008
|
[3]
|
Sánchez-Magraner, L., Gumuzio, J., Miles, J., Quimi, N., Martínez Del Prado, P., Abad-Villar, M.T., et al. (2023) Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 41, 2561-2570.
https://doi.org/10.1200/JCO.22.01748
|
[4]
|
Antony, G.R., Littleflower, A.B., Parambil, S.T. and Subhadradevi, L. (2023) PD-1/PD-L1 Blockade Inhibits Epithelial-Mesenchymal Transition and Improves Chemotherapeutic Response in Breast Cancer. Medical Oncology, 40, Article No. 108. https://doi.org/10.1007/s12032-023-01965-3
|
[5]
|
Yang, L., Zhao, Q., Chen, T., Liu, W., Qiu, X., Chen, J., et al. (2023) An HPK1 Inhibitor Enhanced the Tumour Response to An-ti-PD-1 Immunotherapy in Non-Hodgkin’s Lymphoma. Clinical and Experimental Medicine, 23, 3767-3780.
https://doi.org/10.1007/s10238-023-01068-3
|
[6]
|
Cao, Y., Liang, W., Fang, L., Liu, M.K., Zuo, J., Peng, Y.L., et al. (2022) PD-L1/PD-L1 Signalling Promotes Colorectal Cancer Cell Migration Ability through RAS/MEK/ERK. Clini-cal and Experimental Pharmacology and Physiology, 49, 1281-1293. https://doi.org/10.1111/1440-1681.13717
|
[7]
|
Trefny, M.P., Kaiser, M., Stanczak, M.A., Herzig, P., Savic, S., Wiese, M., et al. (2020) PD-1+ Natural Killer Cells in Human Non-Small Cell Lung Cancer Can Be Activated by PD-1/PD-L1 Blockade. Cancer Immunology, Immunotherapy, 69, 1505-1517. https://doi.org/10.1007/s00262-020-02558-z
|
[8]
|
Gurung, P., et al. (2023) Chlorin e6-Associated Photodynamic Therapy Enhances Abscopal Antitumor Effects via Inhibition of PD-1/PD-L1 Immune Checkpoint. Scientific Reports, 13, Article No. 4647.
https://doi.org/10.1038/s41598-023-30256-0
|
[9]
|
Gurung, P., Lim, J., Shrestha, R. and Kim, Y.W. (2023) Author Correction: Chlorin e6-Associated Photodynamic Therapy Enhances Abscopal Antitumor Effects via Inhibition of PD-1/PD-L1 Immune Checkpoint. Scientific Reports, 13, Article No. 8906. https://doi.org/10.1038/s41598-023-35267-5
|
[10]
|
糜亚琴, 蒋敬庭, 吴昌平. PD-L1/PD-1在卵巢癌中的表达机制及免疫治疗研究进展[J]. 临床肿瘤学杂志, 2017, 22(2): 180-183.
|
[11]
|
Li, X., Zhang, Y., Wang, X., Lin, F., Cheng, X., Wang, Z., et al. (2022) Long Non-Coding RNA CTSLP8 Mediates Ovarian Cancer Progression and Chem-otherapy Resistance by Modulating Cellular Glycolysis and Regulating c-Myc Expression through PKM2. Cell Biology and Toxicology, 38, 1027-1045. https://doi.org/10.1007/s10565-021-09650-9
|
[12]
|
Liu, C., Li, Y., Zhu, Y. and Lu, M. (2022) The Value of IOTA Simple Rules Combined with CEUS Scoring System in the Diagnosis of Benign and Ma-lignant Ovarian Masses and Its Correlation with MVD and VEGF: A Preliminary Study. Journal of Ultrasound in Med-icine, 41, 2983-2992. https://doi.org/10.1002/jum.15999
|
[13]
|
Matsuura, H., Miyamoto, M., Hada, T., Ishibashi, H., Iwahashi, H., Kakimoto, S., et al. (2022) The Worsening Impact of Programmed Cell Death Ligand 1 in Ovarian Clear Cell Carcinomas. Archives of Gynecology and Obstetrics, 306, 2133-2142. https://doi.org/10.1007/s00404-022-06582-5
|
[14]
|
Pfisterer, J., Shannon, C.M., Baumann, K., Rau, J., Harter, P., Joly, F., et al. (2020) Bevacizumab and Platinum-Based Combinations for Recurrent Ovarian Cancer: A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 21, 699-709.
https://doi.org/10.1016/S1470-2045(20)30142-X
|
[15]
|
Zhu, J., Yan, L. and Wang, Q. (2021) Efficacy of PD-1/PD-L1 Inhibitors in Ovarian Cancer: A Single-Arm Meta-Analysis. Journal of Ovarian Research, 14, Article No. 112. https://doi.org/10.1186/s13048-021-00862-5
|
[16]
|
Lee, E.K., Xiong, N., Cheng, S.C., Barry, W.T., Penson, R.T., Konstantinopoulos, P.A., et al. (2020) Combined Pembrolizumab and Pegylated Liposomal Doxorubicin in Plati-num Resistant Ovarian Cancer: A Phase 2 Clinical Trial. Gynecologic Oncology, 159, 72-78. https://doi.org/10.1016/j.ygyno.2020.07.028
|
[17]
|
Liao, J.B., Gwin, W.R., Urban, R.R., Hitchcock-Bernhardt, K.M., Coveler, A.L., Higgins, D.M., et al. (2021) Pembrolizumab with Low-Dose Carboplatin for Recurrent Plati-num-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: Survival and Immune Correlates. The Journal for ImmunoTherapy of Cancer, 9, e003122.
https://doi.org/10.1136/jitc-2021-003122
|
[18]
|
Zhao, F., Fang, T., Liu, H. and Wang, S. (2023) Long Non-Coding RNA MALAT1 Promotes Cell Proliferation, Migration and Invasion in Cervical Cancer by Targeting miR-625-5p and AKT2. Panminerva Medica, 65, 266-267.
https://doi.org/10.23736/S0031-0808.19.03845-X
|
[19]
|
Kagabu, M., Nagasawa, T., Sato, C., Fukagawa, Y., Ka-wamura, H., Tomabechi, H., et al. (2020) Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Fu-ture Directions. International Journal of Molecular Sciences, 21, Article No. 2335. https://doi.org/10.3390/ijms21072335
|
[20]
|
Grau, J.F., Farinas-Madrid, L. and Oaknin, A. (2020) A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemo-therapy plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix: The BEATcc Study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). International Journal of Gynecological Cancer, 30, 139-143.
https://doi.org/10.1136/ijgc-2019-000880
|
[21]
|
Frenel, J.S., Le Tourneau, C., O’Neil, B., Ott, P.A., Piha-Paul, S.A., Gomez-Roca, C., et al. (2017) Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results from the Phase Ib KEYNOTE-028 Trial. Journal of Clinical Oncology, 35, 4035-4041. https://doi.org/10.1200/JCO.2017.74.5471
|
[22]
|
Chung, H.C., Ros, W., Delord, J.P., Perets, R., Ital-iano, A., Shapira-Frommer, R., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cer-vical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478. https://doi.org/10.1200/JCO.18.01265
|
[23]
|
De Felice, F., Giudice, E., Bolomini, G., Distefano, M.G., Scambia, G., Fagotti, A. and Marchetti, C. (2021) Pembrolizumab for Advanced Cervical Cancer: Safety and Efficacy. Expert Review of Anticancer Therapy, 21, 221-228.
https://doi.org/10.1080/14737140.2021.1850279
|
[24]
|
Santin, A.D., Deng, W., Frumovitz, M., Buza, N., Bellone, S., Huh, W., et al. (2020) Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002). Gynecologic Oncology, 157, 161-166. https://doi.org/10.1016/j.ygyno.2019.12.034
|
[25]
|
Eggink, F.A., Van Gool, I.C., Leary, A., Pollock, P.M., Crosbie, E.J., Mileshkin, L., et al. (2017) Immunological Profiling of Molecularly Classified High-Risk Endometrial Cancers Identifies POLE-Mutant and Microsatellite Unstable Carcinomas as Candidates for Checkpoint Inhibition. Oncoim-munology, 6, e1264565.
https://doi.org/10.1080/2162402X.2016.1264565
|
[26]
|
Dizon, D.S., Dias-Santagata, D., Bregar, A., Sullivan, L., Filipi, J., Di Tavi, E., et al. (2018) Complete Remission Following Pembrolizumab in a Woman with Mismatch Re-pair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. Oncologist, 23, 650-653. https://doi.org/10.1634/theoncologist.2017-0526
|
[27]
|
Danley, K., Schmitz, K., Ghai, R., Sclamberg, J.S., Bucking-ham, L.E., Burgess, K., et al. (2021) A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. Oncologist, 26, 811-817. https://doi.org/10.1002/onco.13832
|
[28]
|
Makker, V., Rasco, D., Vogelzang, N.J., Brose, M.S., Cohn, A.L., Mier, J., et al. (2019) Lenvatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer: An Interim Analysis of a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 20, 711-718. https://doi.org/10.1016/S1470-2045(19)30020-8
|
[29]
|
Taylor, M.H., Lee, C.H., Makker, V., Rasco, D., Dutcus, C.E., Wu, J., et al. (2020) Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Car-cinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Journal of Clinical Oncology, 38, 1154-1163. https://doi.org/10.1200/JCO.19.01598
|
[30]
|
刘鸥萱, 胡悦欣, 林蓓. PD-1/PD-L1抑制剂治疗晚期或复发性子宫内膜癌的临床研究进展[J]. 现代肿瘤医学, 2021, 29(8): 1449-1456.
|
[31]
|
Liu, J.F., Gordon, M., Veneris, J., Braiteh, F., Balmanoukian, A., Eder, J.P., et al. (2019) Safety, Clinical Activity and Biomarker Assessments of Atezolizumab from a Phase I Study in Advanced/Recurrent Ovarian and Uterine Cancers. Gynecologic Oncology, 154, 314-322. https://doi.org/10.1016/j.ygyno.2019.05.021
|
[32]
|
Huepenbecker, S.P., Fu, S., Sun, C.C., Zhao, H., Primm, K.M., Giordano, S.H., et al. (2022) Medicaid Expansion and 2-Year Survival in Women with Gynecologic Cancer: A Differ-ence-in-Difference Analysis. American Journal of Obstetrics & Gynecology, 227, 482.e1-482.e15. https://doi.org/10.1016/j.ajog.2022.04.045
|
[33]
|
Borella, F., Preti, M., Bertero, L., Collemi, G., Castellano, I., Cas-soni, P., et al. (2020) Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Re-view. International Journal of Molecular Sciences, 22, Article No. 190. https://doi.org/10.3390/ijms22010190
|
[34]
|
Hecking, T., et al. (2017) Tumoral PD-L1 Expression Defines a Sub-group of Poor-Prognosis Vulvar Carcinomas with Non-Viral Etiology. Oncotarget, 8, 92890-92903. https://doi.org/10.18632/oncotarget.21641
|
[35]
|
Naumann, R.W., Hollebecque, A., Meyer, T., Devlin, M.J., Oaknin, A., Kerger, J., et al. (2019) Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results from the Phase I/II CheckMate 358 Trial. Journal of Clinical Oncology, 37, 2825-2834. https://doi.org/10.1200/JCO.19.00739
|
[36]
|
Cormio, G., Loizzi, V., Gissi, F., Serrati, G., Panzarino, M., Carriero, C., et al. (2009) Cisplatin and Vinorelbine Chemotherapy in Recurrent Vulvar Carcinoma. Oncology, 77, 281-284. https://doi.org/10.1159/000259259
|
[37]
|
Yeku, O., Russo, A.L., Lee, H. and Spriggs, D. (2020) A Phase 2 Study of Combined Chemo-Immunotherapy with Cisplatin-Pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma. Journal of Translational Medicine, 18, Article No. 350. https://doi.org/10.1186/s12967-020-02523-5
|
[38]
|
Shapira-Frommer, R., Mileshkin, L., Manzyuk, L., Penel, N., Burge, M., Piha-Paul, S.A., et al. (2022) Efficacy and Safety of Pembrolizumab for Patients with Previously Treated Advanced Vulvar Squamous Cell Carcinoma: Results from the Phase 2 KEYNOTE-158 Study. Gynecologic Oncology, 166, 211-218.
https://doi.org/10.1016/j.ygyno.2022.01.029
|
[39]
|
Bogani, G., Palaia, I., Perniola, G., Tomao, F., Giancotti, A., Di Mascio, D., et al. (2023) An Update on Current Pharmacotherapy for Vulvar Cancer. Expert Opinion on Pharmacother-apy, 24, 95-103.
https://doi.org/10.1080/14656566.2022.2117608
|